Background Psychedelic therapy shows promise for Major Depressive Disorder, especially
when treatment-resistant, as well as life-threatening illness distress. The objective of this …

Introduction Bipolar disorder (BD) is a chronic mental illness impacting 1–2% of the
population worldwide and causing high rates of functional impairment. Patients with BD …

We conducted a meta-analysis using individual participant data from three, two-dose
psilocybin trials for depression (N= 102) with the aim of assessing the risk of symptom …

Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic
potential for treatment of psychiatric illness. We conducted the first comprehensive …

The past 15 years have witnessed an enthusiastic revival of research into the therapeutic
potential of psychedelic drugs (eg psilocybin, MDMA) for people with serious psychiatric and …

Importance Psilocybin has been studied in the treatment of depression and anxiety
disorders. Clinical studies have mainly focused on efficacy, with systematic reviews showing …

Australian & New Zealand Journal of Psychiatry, 00 (0) considered but in a study of MDMA
for alcohol use disorder, over 90% of participants and therapists correctly guessed allocation …

There has been a resurgence in psychedelic research for managing psychiatric conditions
in recent years. This study aimed to present a comprehensive review of the current state of …

There is much excitement surrounding recent research of promising, mechanistically novel
psychotherapeutics–psychedelic, anesthetic, and dissociative agents–as they have …

Background: The classical psychedelics psilocybin, peyote, ayahuasca/N, N-
dimethyltryptamine, and lysergic acid diethylamide can temporarily produce altered states of …